2025 Best of Show Entries
Advanced Electrophoresis Solutions Ltd. | CEInfinite icIEF | Booth 626
https://aeslifesciences.com/
High-efficient charge variant separation to large-scale icIEF fractionation for protein heterogeneity in-depth characterization and critical reagents powering high-precision analysis to MS-integrated icIEF for accurate intact protein identification.
Bruker Cellular Analysis | Beacon Discovery | Booth 217
https://brukercellularanalysis.com/products/instruments/beacon-discovery-optofluidic-system/
Single-cell functional analysis is essential for uncovering the behavior of individual cells. It complements cellular transcriptomics analysis by providing critical insights that empower researchers to discover complex biological processes and diseases. Beacon Discovery™, a new breakthrough benchtop system designed to democratize live single-cell functional analysis from Bruker Cellular Analysis, is powered by proven Opto-Electro Positioning (OEP®) technology, enabling serial multi-parameter functional analysis on live single cells and accelerating discoveries in immune profiling, cell therapy, and antibody discovery. Beacon Discovery delivers the power of longitudinal single-cell functional analysis in a compact format with lower cost of ownership. By prioritizing accessibility and ease-of-use, Beacon Discovery opens the door for academic labs, biotech innovators, and translational researchers to push the boundaries of T-cell profiling and CAR/TCR discovery, antibody discovery and profiling, cell therapy development, and infectious and autoimmune disease research. Using Beacon Discovery, researchers can run real-time sequential multiplexed assays on the same live-cell single cells and ultimately link functional phenotypes to transcriptomic or genomic signatures, all within an intuitive workflow tailored to labs. Beacon Discovery offers a function-first, total solution for rapid antibody discovery and profiling. Its high-throughput, single-day workflow supports broad species compatibility and comprehensive assays. The platform enables fast, automated screening to prioritize functional antibodies, maximize discovery success, and expand assay applicability. With the new interchangeable filter cubes and automated sample handling, Beacon Discovery delivers dynamic, real-time monitoring of immune responses, offering insights into antibody evolution during disease or vaccination. Assays include antigen specificity, affinity ranking, cross-reactivity, ligand-blocking, and internalization, empowering researchers to identify top therapeutic candidates with high precision and speed. This integrated approach revolutionizes both discovery and characterization of antibodies.
Constant Systems | CF Continuous Flow Cell Disruption System | Booth 28
https://constantsystems.com/products/continuous-flow-cell-disruptor/
Cell disruption is a critical step in biotechnological research, impacting the efficiency of downstream processes. Why Constant Systems are leagues ahead of the competition: Our high-pressure cell disruptors ensure up to 99% of the sample is processed at the target pressure.
*The precise control of pressure minimizes shear forces, reducing the risk of sample degradation and loss. *Guarantees consistent and reproducible results, enhancing the reliability of research outcomes.
*Considered engineering and cooling maintains integrity of your protein extraction for downstream analytics.
*Our product range supports both small-scale (0.5mL) and large-scale (up to 150L/hour) processing.
Deeptope | Epitope Mapping by Deep Mutational Scanning | Booth 719
https://deeptope.com/epitope-mapping/
METHODOLOGY
- A setup is designed to ensure that the antigen is correctly expressed (several antigen sequences/subdomains can be expressed) and that it binds to the antibody (or antibodies) whose epitope is to be mapped (for each antibody, apparent KD and binning will be evaluated).
- Epitope mapping: in vitro evaluation of the impact of each mono-substitution of an amino acid (AA) by the 19 other natural ones at each AA position of the antigen sequence (on the modification of the binding to its ligand - mAb, VHH, cytokine...). A library of single antigen mutants is generated, expressed on the yeast surface, then sorted by Facs in the presence of the ligand; the sorted populations are then deep-sequenced, to establish a Deep Mutational Scanning map (a map that shows the impact of each AA substitution, at each AA position of the protein sequence, on the interaction with the ligand); the epitope residues are then shown on the protein structure.
BENEFITS:
- This in vitro method is as accurate as crystallography (to the nearest AA).
- It is similar to the alanine scanning approach, except that instead of analyzing single AA substitution (alanine), each of the other 19 natural AAs are substituted and tested at each AA position in the protein sequence (it is more robust than alanine scanning and provides deeper information).
- It is useful to predict cross reactivity, viral escape.
- It is fast and cost effective, when several epitopes have to be identified on the same antigen (the same antigen single-mutant library can be used, stored and re-used for several antibodies).
Demeetra | Cas-CLOVER | Booth 80
https://demeetra.com/cas-clover/
Cas-CLOVER directly addresses CRISPR/Cas9’s biggest challenge in cell line development (CLD): freedom to operate (FTO). With a complex and restricted CRISPR IP landscape, biotech and biopharma teams face costly barriers to commercialization. Cas-CLOVER offers a smarter solution: a CRISPR-based editing system that combines technical strength with a robust FTO position. At the core is a unique dual-nuclease design: catalytically inactive Cas9 (dCas9) fused to the proprietary Clo051 nuclease. This dimeric system requires two guide RNAs to activate cutting, which enables greater knockout and targeted integration efficiency, with published data showing >90% knockout rates and improved knock-in performance compared to Cas9. Cas-CLOVER’s gRNA design is intuitive and familiar to users of CRISPR/Cas9, allowing for easy adoption into existing workflows without extensive optimization. The system’s built-in specificity also results in low background activity, helping ensure clean, reproducible edits. What truly sets Cas-CLOVER apart is its IP positioning. It can be uniquely paired with foundational CRISPR/Cas9 rights from the CVC, providing unmatched FTO for CLD applications. Technical Highlights:
• Alternative to CRISPR/Cas9 with full FTO for CLD
• Unique dual-nuclease mechanism enhances knockout and knock-in efficiency
• Easy-to-use, CRISPR-based gRNA design
• Flexible, nonrestrictive licensing options Cas-CLOVER is the editing solution that combines performance, simplicity, and commercial freedom, giving cell line developers the confidence to scale.
DIMA Biotechnology LLC | Antibody-Drug Conjugate (ADC) Antibody Screening Reagents | Booth 820
https://www.dimabio.com/reagents-for-adc-internalization-assay
This latest release of ADC Antibody Screening Reagents introduces two major innovations to streamline ADC antibody discovery:
1. Cytotoxic Payload-Conjugated IgG Labeling Reagent – This newly released reagent features a pre-conjugated cytotoxic payload (MMAE) that binds universally to testing IgGs. It mimics ADC-like activity, enabling early evaluation of both internalization and cytotoxic potency—without the need to individually conjugate cytotoxic payloads to each antibody.
2. Optimized pH-Sensitive IgG Labeling Reagent Plus – An enhanced version of our widely used pH-sensitive dye-based reagent, this upgrade offers improved signal stability and broader compatibility across IgG subtypes. It allows researchers to rank antibody internalization potency based on fluorescence intensity triggered in acidic intracellular compartments. Together, these tools provide a faster, more efficient path to identifying highly potent ADC antibodies.
DPBIO | CytoSpark® CSP Microfluidic High-throughput Screening System | Booth 410
https://dp-bio.com/platform?id=1
The CytoSpark® CSP system leverages advanced droplet microfluidics to partition liquids into millions of picoliter-scale droplets, each encapsulating individual cells for single-cell analysis. This enables precise detection of cells secreting specific antibodies or exhibiting particular functions. Utilizing fluorescence activation and dielectrophoretic sorting, the system efficiently identifies and isolates positive droplets. It supports various recovery methods, including 96-well plate printing and bulk collection, accommodating diverse project needs. Key Features and Technical Specifications: Accelerated R&D Cycle: Completes B cell screening within a single day, significantly reducing development time and costs compared to traditional methods. Ultra-High Throughput: Processes millions of B cells per screening, enhancing efficiency and preserving the diversity of positive B cells. High Compatibility: Supports both 96-well plate dispensing and bulk collection, offering flexibility for various project requirements. Natural Heavy and Light Chain Pairing: Maintains antibody stability, functionality, and affinity. Enhanced Accuracy: Employs multiple lasers to reduce false positives and improve screening precision. Broad Applicability: Suitable for various antigens, including soluble and transmembrane proteins, and supports cross-species and functional antibody development. Flexible Species Application: Adaptable for monoclonal antibody development across multiple species, such as mice, rabbits, camels, and alpacas. The CytoSpark® CSP system represents a significant advancement in high-throughput screening technology, offering rapid, accurate, and versatile solutions for antibody discovery and functional cell analysis.
LenioBio| ALiCE for High-Throughput Protein Expression | Booth 720
https://www.leniobio.com/
ALiCE® for High-Throughput Protein Expression (ALiCE® HTPE) – is a LenioBio platform technology that produces the most difficult and challenging proteins, in full size and fully functional, in just 24 hours. It is the first scalable eukaryotic cell-free expression platform specifically engineered for rapid antibody discovery and screening. This comprehensive solution matches the speed of AI-driven innovation enabling 10X faster workflows, 90%+ success rate for complex/ DTE proteins and >50% cost reduction in antibody development versus the traditional methods. By offering an end-to-end service covering DNA template generation, lead generation, purification and analysis, this new solution reduces production timelines from 4 weeks to 3 days. ALiCE® HTPE is compatible with linear, plasmid or synthetic DNA templates. As drug development pipelines grow in complexity and speed, discovery teams face intense pressure to generate high-quality leads faster. ALiCE® HTPE removes common bottlenecks, such as transfection inefficiencies and slow expression, bypassing cell culture altogether, enabling rapid, parallel synthesis of diverse antibody formats, including monoclonal Abs, VHH nanobodies, Fabs, and multi-specific Antibodies ALiCE® HTPE is designed for a seamless integration in current workflows plugging out cell-based steps and plugging in ALiCE®, supporting life science and biopharmaceutical innovators, to rapidly translate AI-assisted protein designs into reliable protein constructs. The scale ranges from microliter screening to liter-scale production addresses needs from early discovery to pre-clinical development. LenioBio provides all researchers a faster, scalable, and open platform democratizing protein expression regardless of cell culture capabilities and propels next-generation antibody discovery worldwide.
LiveDrop sa | ModaFlow 4L5C | Booth 825
https://www.livedrop-bio.com/products/modaflow
ModaFlow 4L5C sets a new 2025 benchmark in high-throughput droplet sorting, building on the 2023 release with expanded detection via 4 lasers and 5 PMTs. This innovation boosts multiplexing on the LiveDrop platform while preserving assay flexibility. Combined with zero dead volume, an intuitive control interface, and compatibility with a broad range of bioassays (agonist screening, reporter activation, target binding, secretion, FRET, enzyme activity), ModaFlow 4L5C becomes the standout tool for R&D in antibody discovery, secretome analysis, and single-cell immune profiling.
NanoTemper Technologies | Prometheus Panta C | Booth 420
https://resources.nanotempertech.com/page/prometheus-panta-c
Prometheus Panta C is a system built to power biopharma breakthroughs by delivering high-quality protein stability and aggregation data with the precision and efficiency needed throughout the drug development process — from preclinical phase to commercial manufacturing. Combining four advanced optical technologies already available in Prometheus Panta – nanoDSF, DLS, SLS, and Backreflection – Prometheus Panta C now offers features that support data integrity and 21 CFR part 11 compliance. The instrument streamlines developability assessments, process monitoring, and protein identity characterization; all while requiring minimal sample volume. Prometheus Panta C facilitates data integrity through distinct user access groups, while Active Directory integration provides centralized user authentication. Features such as electronic signatures, electronic records, and comprehensive audit trails further strengthen regulatory alignment. Fully compatible with LIMS, automation platforms, and both low- and high-throughput workflows, Prometheus Panta C supports scalable, data-driven analysis. It delivers critical data in under two hours, accelerating decision-making, reducing risk, and helping bring biologics to market faster. Visit our dedicated Prometheus Panta C webpage to find out more details: https://resources.nanotempertech.com/page/prometheus-panta-c
Neochromosome | Opentrons Flex neoSwitch Workstation | Booth 29
https://opentrons.com/our-partners/neochromosome
Neochromosome, together with its parent company Opentrons Labworks, proudly introduces the Opentrons Flex neoSwitch Workstation, a fully integrated yeast display and robotic liquid handling platform engineered specifically to accelerate antibody discovery workflows in-house. At the heart of this innovation lies Neochromosome’s proprietary neoSwitch platform, an engineered yeast strain uniquely capable of rapidly toggling between antibody cell-surface display and protein secretion. In secretion mode, neoSwitch generates sufficient protein yields for many assays employed during initial hit characterization—completely eliminating the need for traditional and labor-intensive subcloning steps typically required prior to protein expression. neoSwitch can be delivered pre-transformed with large naïve discovery libraries (including formats such as VHH and scFv) and has demonstrated versatility in successfully displaying and secreting novel formats, notably TCR-like fragments. Leveraging Opentrons Flex’s advanced AI-driven robotic liquid handling capabilities, labs can now execute complete antibody screening campaigns—from rapid hit purification to streamlined downstream processing and characterization—in just weeks, compared to the traditional timelines of a year or longer with conventional CRO-managed workflows. By automating repetitive laboratory tasks such as liquid transfers, incubation scheduling, and media exchanges, the Flex neoSwitch Workstation significantly enhances reproducibility, increases throughput, and frees researchers to concentrate on more important activities such as data analysis and decision-making. Key Benefits & Advantages: -Drastically accelerates antibody discovery timelines. -Eliminates labor-intensive subcloning prior to initial protein characterization. -Supports multiple antibody formats, enabling exploration of novel targets. -Increases workflow efficiency, reproducibility, and throughput. -Frees scientific personnel to focus on analysis rather than routine laboratory tasks.
PAIA Biotech GmbH | FcRn binding and release assay | Booth 521
http://paiabio.com
We are presenting a new assay based on the PAIA microplate technology. It is an addition to the existing portfolio of high throughput developability assays by PAIA and allows for the detection of the pH-dependent binding and release of antibodies to the FcRn receptor in a simple and entirely microplate-based workflow. This receptor is crucial for the intracellular recycling of antibodies and a main determinant of antibody clearance. The assay measures the binding to immobilized FcRn at four different pH levels in separate wells and only small amounts of sample (1µg of protein). The assay results is a desorption curve which allows for the determination of the pH at which the antibodies are released from the receptor. Ideal molecules show strong binding at acidic pH levels and no binding at neutral pH, which guarantees efficient recycling. This is the first assay to provide this type of critical data on the FcRn interaction and is considered a replacement of FcRn chromatography which is costly and a factor of 100 slower.
Partillion Bioscience | Nanovial Multicell Assays | Booth 121
https://www.partillion.com/multicell-assays
Nanovial Multicell Assays enable high-throughput functional screening of hundreds of thousands of antibody-secreting cells in a biologically relevant context without the need for microfluidics. In this latest release, nanoliter-scale hydrogel compartments, known as Nanovials, are used to co-localize multiple cells—such as antibody-secreting cells and target-expressing reporter or antigen-presenting cells—within individual compartments by simple mixing in a tube. These confined microenvironments support parallel screening of cell-cell interactions, capturing secreted products and enabling functional assessment based on true biological activity rather than binding alone. Compatible with standard flow cytometers, spectral sorters, and imaging cytometry platforms, the assay allows precise, function-based sorting using readouts such as cytokine secretion or fluorescent reporter activation. Each ~50-micron Nanovial is engineered to reproducibly pair two to three cells per particle and maintain viability throughout the workflow, enabling downstream expansion or sequencing. The platform supports single-cell recovery and integration with multiomic workflows, allowing researchers to link gene expression, V(D)J repertoires, and functional phenotypes from the same cell. This empowers rapid identification and characterization of high-value antibody candidates, including those targeting complex antigens like GPCRs or requiring dual-cell engagement, such as bispecifics. Reagents are optimized for use with hybridomas, primary B cells, and engineered cell lines, and fit seamlessly into existing antibody discovery pipelines. By uniting biological relevance, scalability, and multiomic compatibility, Nanovial Multicell Assays offer a powerful, plug-and-play solution to uncover therapeutic antibodies that conventional screening approaches often miss.
ProBioGen | Smart Automation Solution | Booth 810
https://www.probiogen.de/
Smart Automation Solution for Faster Selection of Producer Clones with Superior Quality ProBioGen’s smart automation solution enables exceptionally early screening for USP platform fit and key product quality attributes. The intelligent, modular system identifies high-performing clones with desired quality profiles, far earlier than traditional workflows. It delivers superior, high quality producer clones faster and eases the transition to manufacturing. Built around a Biomek i7 robotic system, the automation solution integrates the entire workflow from 384-well plates to shaken deep well batch processes and includes shaking incubators and analytical devices. It covers liquid handling, on-demand feeding, real-time monitoring of cell density, viability, metabolites and titers, and high-throughput sampling for in-depth product analysis. The system allows for early, parallel screening of large clone panels against key quality attributes like biosimilarity and heterodimer levels, providing information to select the right clones far earlier than conventional methods. This smart innovation in cell line development automation unfolds its full potential when combined with ProBioGen's CHO.RiGHT® platform. Since the DirectedLuck® transposase delivers the highest productivity, the screening focus can now be shifted to product quality, which is facilitated by the automated system. Clones selected through this workflow have demonstrated exceptional productivity, achieving already very high titers under non-optimized conditions, while consistently meeting quality criteria. Their performance remains stable through scale-up and into GMP production. This system is not just another automation solution; it’s a strategic enabler that empowers you to select better clones and speed to clinic with greater efficiency and confidence.
Promega Corporation | Lumit® FcγR Binding Immunoassays | Booth 306
https://www.promega.com/products/immunoassay-elisa/lumit-immunoassays/lumit-fcgr-binding-immunoassays/?catNum=CS3041A01
The Lumit® FcγR Binding Immunoassays are novel competition assays to measure the interaction between human Fc receptors and antibodies or Fc fusion proteins. Lumit® FcγR Binding assays are based on a split luciferase technology that offer a quick, simple, no-wash alternative to ELISAs to be used for antibody discovery and under GMP conditions for biologics manufacturing applications. We’re introducing a full repertoire of Lumit® assays for Fc receptor characterization: FcγRI, FcγRIIa (H131), FcγRIIa (R131), FcγRIIIa (V158), FcγRIIIa (F158), FcγRIIb, and FcγRIIIb to provide a thorough understanding of your antibody's potential immune effector function, aiding in the optimization of therapeutic antibodies for desired clinical outcomes.
Proteome Sciences | Solvent Shift Assay for Proteome-wide Target Engagement Studies | Booth 616
http://www.proteomics.com
Solvent Shift Assay. As per the following reference1, the solvent shift assay is a variant on the thermal shift and can be applied toward proteome-wide target engagement studies. Increasing concentrations of organic solvents stimulate unfolding and precipitation of the cellular proteome. This property can be influenced by physical association with ligands and other molecules, making individual proteins more or less susceptible to solvent-induced denaturation. Gygi1 reports the development of proteome-wide solvent shift assays by combining the principles of solvent-induced precipitation (Zhang et al., 2020) with modern quantitative proteomics. Using this approach, the authors developed solvent proteome profiling (SPP), which is capable of establishing target engagement through analysis of SPP denaturation curves. The authors readily identified the specific targets of compounds with known mechanisms of action. As a further efficiency boost, they applied the concept of area under the curve analysis to develop solvent proteome integral solubility alteration (solvent-PISA) and demonstrate that this approach can serve as a reliable surrogate for SPP. Its propose that by combining SPP with alternative methods, like thermal proteome profiling, it will be possible to increase the absolute number of high-quality melting curves that are attainable by either approach individually, thereby increasing the fraction of the proteome that can be screened for evidence of ligand binding. 1. Van Vranken, Li, et al. eLife 2021;10:e70784. DOI: https:// doi. org/ 10. 7554/ eLife. 70784
Rapid Novor, Inc. | REpAb® Mass Spectrometry-Based Antibody Discovery: Profiling Human Serum and Idiotypic Immune Responses | Booth 309
http://www.rapidnovor.com
Product Description: We are introducing an innovative "Test-then-Make" antibody discovery approach that transforms traditional workflows. Our proprietary REpAb technology combines de novo protein sequencing with proteogenomics to identify functional/neutralizing antibodies directly from polyclonal samples, bypassing the limitations of conventional B-cell isolation methods. What's New: The first de novo sequencing of human serum antibody proteins finds neutralizing antibodies - published in Nature Communications in Oct 2024. Breakthrough methodology reversing the traditional "Make-then-Test" paradigm by pre-selecting antibody functionality before sequencing and synthesis. REpAb’s novel workflow specifically for anti-idiotypic antibody discovery - launching at PEGS 2025. Uses the protein for idiotype specific enrichment and depletion followed by polyclonal sequencing and demonstrates significant improvement in idiotypic antibody performance against adilumumab. Technical Specifications: Advanced de novo sequencing algorithms to reconstruct complete antibody sequences from polyclonal mixtures Customizable selection strategies for specific characteristics (stability, pH dependence, cross-reactivity). Sequencing real natural functional antibodies instead of or as well as RNA extracted from early intermediate B-cells. Ability to go beyond the 2% B-cells in circulation in blood. Proprietary heavy-light chain pairing technology. Experimentally validated heavy-light chain pairing system using direct evidence of physical association rather than computational prediction. Demonstrated success in identifying neutralizing SARS-CoV-2 antibodies derived directly from patient serum. Novel anti-kappa light chain dimer antibodies for LCMM with 100 to 1000x higher specificity. Specialized anti-idiotypic antibody discovery with type-specific enrichment. Early Go/No-Go decision points minimizing resources on non-viable candidates. Compatible with multiple species and antibody formats. Integrates with existing downstream validation workflows.
Sartorius | Octet® R8e | Booth 609
https://www.sartorius.com
The Octet® R8e system is the newest instrument in biolayer interferometry that can be used for a wide range of analyses, such as kinetic analysis, titer of IgG and other proteins, reagent qualification, immunoassay development, bioprocess development, quality control, crude antibody screening, epitope binning/mapping, ligand binding assays, small molecule analysis, elucidating cell signaling mechanisms, and infectious disease monitoring. Scientists can perform analysis using a single channel or up to eight channels, giving them flexibility in sample throughput. Out of the many BLI instruments on the market, the Octet® R8e system delivers unmatched sensitivity, extended runtimes, and the fastest data acquisition rates, which all contribute to accurate data that enables researchers to tackle more complex assays with confidence.
Scala Biodesign | ScalaOS | Booth 34
http://www.scala-bio.com
Scala Biodesign expands the boundaries of protein engineering by enabling the design of proteins that were previously out of reach. Our protein design platform combines AI, atomistic calculations, and evolutionary analysis to improve the stability and activity of antibodies, enzymes, vaccines, drug targets, and other complex proteins. Scala’s one-shot protein design technologies break the prevailing design-test-learn engineering paradigm by encoding multiple synergistic mutations through a single design round, low throughput experiments and without the need for preliminary data. Scala’s protein design platform has been rigorously validated by over 130 peer-reviewed publications, including a vaccine candidate in PII clinical trials and enzyme therapies in pre-clinical studies. Scala is currently working with five of the largest pharmaceutical companies, including Boehringer Ingelheim, to repeatedly solve complex protein engineering bottlenecks. Scala technologies are applicable to diverse protein engineering challenges, including: Therapeutic antibodies in different modalities- Improving developability, activity, and stability. Soluble and membrane drug targets- Enabling expression, stabilization, and crystallization without compromising protein activity. Enzyme therapies and vaccines- Increasing stability and potency. Scala now offers a no-code protein design software platform to enable R&D teams to design their drug targets independently and at scale. For biotherapeutics, Scala’s team of expert protein designers works collaboratively to address the dedicated needs of various development programs.
Thermo Fisher Scientific | GeneArt HTP Antibody Expression Service | Booth 425
https://www.thermofisher.com/us/en/home/life-science/cloning/gene-synthesis/geneart-antibody-expression-services.html
Our new semi-automated, high-throughput platform enables reproducible and rapid production of antibodies from transiently transfected mammalian cells, while remaining flexible enough to address the needs of the rapidly evolving immunotherapy field. As with our mid- and large-scale protein expression services, high yields are achieved with a combination of our world-class sequence optimization and high-efficiency Gibco ExpiCHO or Expi293 expression systems.
Deliverables
- 0.1–1 mg of each antibody in Matrix 2D barcoded tubes (default)
- 5 µg of plasmid DNA Production time
- ≤20 business days including gene synthesis and protein purification Purification options
- Supernatant
- One-step protein A/G purification QC analytics
- Purified antibodies - Purity assessment (CE-SDS), Total protein quantitation using UV/Vis-DLS Stunner, Volume determination by ultrasonic distance measurement
- Supernatant - Octet BLI titer measurement, Volume determination by ultrasonic distance measurement Optional add-ons
- Alternative delivery in 96-well deep well plate or FluidX tubes
- Endotoxin measurement
- In-process Octet BLI titer measurement for purified antibodies
WuXi Biologics | True Four Chain (TFC) Quick ‘n’ Clean | Booth 700
https://www.wuxibiologics.com/capabilities/protein-sciences/bispecific-antibody-production/#quick
Producing bispecific antibodies (bsAbs) poses challenges in throughput, yield, and purity, especially for four-chain bsAbs containing two different LCs, due to the high risk of chain mispairing. The TFC Quick ‘n’ Clean platform, leveraging the WuXiBody™ format, addresses these challenges by ensuring correct LC-HC pairing, yielding bsAbs free of LC mispairing. This next-generation tool enables high-throughput bsAb production, facilitating rapid identification of optimal pairings of true four-chain bsAbs. Technical Specifications: Molecular engineering: The WuXiBody™ format replaces the CH1/CL region of one parental mAb with a TCR constant domain to prevent LC mispairing. In the double-tagged format, Flag and His tags are incorporated to facilitate efficient purification. In the non-tagged format, FcRn-null mutations are introduced in the Fab-arm Fc region, and codon optimization reduces TCR arm expression, thereby ensuring the selective overexpression of Fab-arm-related byproducts. Expression: This platform leverages ultra-high-titer CHO transient expression systems, producing 1-7 mg of bsAbs from 20 mL CHO cultures within 3-4 weeks, providing exceptional throughput and yield for four-chain bsAbs. Purification: For double-tagged bsAbs, Ni-Anti-DYKDDDDK-SEC purification removes homodimers and half-antibodies, achieving >99% heterodimer purity as confirmed by LC-MS. For non-tagged bsAbs, ProA-SEC purification eliminates Fab-arm-related byproducts that don’t bind to ProA, also ensuring >99% heterodimer purity. Together, as the first innovative platform designed for high-throughput, high-purity production of true four-chain bsAbs in both double-tagged and non-tagged formats, TFC Quick ‘n’ Clean represents a groundbreaking advancement that rapidly unlocks optimal pairings of bsAbs in early-stage drug discovery.